aTYR PHARMA INC Research and Development Expense
aTYR PHARMA INC (ATYR) reported Research and Development Expense of $6.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- aTYR PHARMA INC research and development expense for the quarter ending 2026-06-30 was $6.75M, a 56.14% decline year-over-year.
- aTYR PHARMA INC research and development expense for the quarter ending 2026-03-31 was $7.32M, a 38.07% decline year-over-year.
- aTYR PHARMA INC research and development expense for the quarter ending 2025-12-31 was $10.89M, a 10.93% decline year-over-year.
- aTYR PHARMA INC research and development expense for the quarter ending 2025-09-30 was $22.13M, a 49.46% increase year-over-year.
- aTYR PHARMA INC research and development expense for fiscal 2025 was $60.22M, a 10.75% increase from fiscal 2024.
- aTYR PHARMA INC research and development expense for fiscal 2024 was $54.37M, a 28.56% increase from fiscal 2023.
- aTYR PHARMA INC research and development expense for fiscal 2023 was $42.29M, a 1.20% decline from fiscal 2022.
- aTYR PHARMA INC research and development expense for fiscal 2022 was $42.81M, a 84.01% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.75M 10-Q · filed 2026-08-07 | $14.06M 10-Q · filed 2026-08-07 | $24.96M derived: sum of 3 quarters · filed 2026-08-07 | $47.09M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $7.32M 10-Q · filed 2026-05-15 | $18.21M derived: sum of 2 quarters · filed 2026-05-15 | $40.34M derived: sum of 3 quarters · filed 2026-05-15 | $55.72M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $33.02M derived: sum of 2 quarters · filed 2026-03-05 | $48.41M derived: sum of 3 quarters · filed 2026-08-07 | $60.22M 10-K · filed 2026-03-05 |
| 2025-09-30 | $22.13M 10-Q · filed 2025-11-06 | $37.51M derived: sum of 2 quarters · filed 2026-08-07 | $49.33M 10-Q · filed 2025-11-06 | $61.56M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $15.38M 10-Q · filed 2026-08-07 | $27.20M 10-Q · filed 2026-08-07 | $39.43M derived: sum of 3 quarters · filed 2026-08-07 | $54.23M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $11.81M 10-Q · filed 2026-05-15 | $24.04M derived: sum of 2 quarters · filed 2026-05-15 | $38.85M derived: sum of 3 quarters · filed 2026-05-15 | $52.82M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $12.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $27.04M derived: sum of 2 quarters · filed 2026-03-05 | $41.01M derived: sum of 3 quarters · filed 2026-03-05 | $54.37M 10-K · filed 2026-03-05 |
| 2024-09-30 | $14.81M 10-Q · filed 2025-11-06 | $28.78M derived: sum of 2 quarters · filed 2025-11-06 | $42.14M 10-Q · filed 2025-11-06 | $54.90M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $13.97M 10-Q · filed 2025-08-07 | $27.34M 10-Q · filed 2025-08-07 | $40.09M derived: sum of 3 quarters · filed 2026-03-05 | $50.41M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $13.36M 10-Q · filed 2025-05-07 | $26.12M derived: sum of 2 quarters · filed 2026-03-05 | $36.44M derived: sum of 3 quarters · filed 2026-03-05 | $46.28M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $12.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $23.07M derived: sum of 2 quarters · filed 2026-03-05 | $32.91M derived: sum of 3 quarters · filed 2026-03-05 | $42.29M 10-K · filed 2026-03-05 |
| 2023-09-30 | $10.32M 10-Q · filed 2024-11-07 | $20.16M derived: sum of 2 quarters · filed 2024-11-07 | $29.54M 10-Q · filed 2024-11-07 | $44.45M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $9.84M 10-Q · filed 2024-08-13 | $19.22M 10-Q · filed 2024-08-13 | $34.13M derived: sum of 3 quarters · filed 2025-03-13 | $44.00M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $9.38M 10-Q · filed 2024-05-02 | $24.29M derived: sum of 2 quarters · filed 2025-03-13 | $34.16M derived: sum of 3 quarters · filed 2025-03-13 | $43.29M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $14.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $24.78M derived: sum of 2 quarters · filed 2025-03-13 | $33.91M derived: sum of 3 quarters · filed 2025-03-13 | $42.81M 10-K · filed 2025-03-13 |
| 2022-09-30 | $9.87M 10-Q · filed 2023-11-09 | $19.00M derived: sum of 2 quarters · filed 2023-11-09 | $27.90M 10-Q · filed 2023-11-09 | $33.85M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $9.13M 10-Q · filed 2023-08-09 | $18.03M 10-Q · filed 2023-08-09 | $23.99M derived: sum of 3 quarters · filed 2024-03-14 | $29.12M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $8.90M 10-Q · filed 2023-05-09 | $14.85M derived: sum of 2 quarters · filed 2024-03-14 | $19.99M derived: sum of 3 quarters · filed 2024-03-14 | $27.64M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $11.09M derived: sum of 2 quarters · filed 2024-03-14 | $18.75M derived: sum of 3 quarters · filed 2024-03-14 | $23.26M 10-K · filed 2024-03-14 |
| 2021-09-30 | $5.14M 10-Q · filed 2022-11-14 | $12.79M derived: sum of 2 quarters · filed 2022-11-14 | $17.31M 10-Q · filed 2022-11-14 | $22.01M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-06-30 | $7.66M 10-Q · filed 2022-08-15 | $12.17M 10-Q · filed 2022-08-15 | $16.87M derived: sum of 3 quarters · filed 2023-03-14 | $21.48M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-03-31 | $4.52M 10-Q · filed 2022-05-10 | $9.21M derived: sum of 2 quarters · filed 2023-03-14 | $13.83M derived: sum of 3 quarters · filed 2023-03-14 | $18.19M derived: sum of 4 quarters · filed 2023-03-14 |
| 2020-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $9.31M derived: sum of 2 quarters · filed 2023-03-14 | $13.68M derived: sum of 3 quarters · filed 2023-03-14 | $17.29M 10-K · filed 2023-03-14 |
| 2020-09-30 | $4.62M 10-Q · filed 2021-11-12 | $8.98M derived: sum of 2 quarters · filed 2021-11-12 | $12.59M 10-Q · filed 2021-11-12 | $16.18M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $4.36M 10-Q · filed 2021-08-11 | $7.98M 10-Q · filed 2021-08-11 | $11.57M derived: sum of 3 quarters · filed 2022-03-15 | $15.37M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $3.62M 10-Q · filed 2021-05-14 | $7.21M derived: sum of 2 quarters · filed 2022-03-15 | $11.01M derived: sum of 3 quarters · filed 2022-03-15 | $14.32M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $7.39M derived: sum of 2 quarters · filed 2022-03-15 | $10.70M derived: sum of 3 quarters · filed 2022-03-15 | $14.05M 10-K · filed 2022-03-15 |
| 2019-09-30 | $3.80M 10-Q · filed 2020-11-13 | $7.11M derived: sum of 2 quarters · filed 2020-11-13 | $10.46M 10-Q · filed 2020-11-13 | $14.01M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-06-30 | $3.31M 10-Q · filed 2020-08-13 | $6.66M 10-Q · filed 2020-08-13 | $10.21M derived: sum of 3 quarters · filed 2021-03-24 | $14.41M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-03-31 | $3.35M 10-Q · filed 2020-05-12 | $6.89M derived: sum of 2 quarters · filed 2021-03-24 | $11.10M derived: sum of 3 quarters · filed 2021-03-24 | $17.58M derived: sum of 4 quarters · filed 2021-03-24 |
| 2018-12-31 | $3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $7.75M derived: sum of 2 quarters · filed 2021-03-24 | $14.23M derived: sum of 3 quarters · filed 2021-03-24 | $20.39M 10-K · filed 2021-03-24 |
| 2018-09-30 | $4.20M 10-Q · filed 2019-11-14 | $10.69M derived: sum of 2 quarters · filed 2019-11-14 | $16.84M 10-Q · filed 2019-11-14 | $22.15M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $6.48M 10-Q · filed 2019-08-14 | $12.63M 10-Q · filed 2019-08-14 | $17.94M derived: sum of 3 quarters · filed 2020-03-26 | $25.08M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | $6.15M 10-Q · filed 2019-05-14 | $11.46M derived: sum of 2 quarters · filed 2020-03-26 | $18.59M derived: sum of 3 quarters · filed 2020-03-26 | $27.01M derived: sum of 4 quarters · filed 2020-03-26 |
| 2017-12-31 | $5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $12.44M derived: sum of 2 quarters · filed 2020-03-26 | $20.86M derived: sum of 3 quarters · filed 2020-03-26 | $30.07M 10-K · filed 2020-03-26 |
| 2017-09-30 | $7.13M 10-Q · filed 2018-11-14 | $15.55M derived: sum of 2 quarters · filed 2018-11-14 | $24.76M 10-Q · filed 2018-11-14 | $33.90M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-06-30 | $8.42M 10-Q · filed 2018-08-14 | $17.62M 10-Q · filed 2018-08-14 | $26.77M derived: sum of 3 quarters · filed 2019-03-26 | $37.16M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-03-31 | $9.20M 10-Q · filed 2018-05-15 | $18.35M derived: sum of 2 quarters · filed 2019-03-26 | $28.74M derived: sum of 3 quarters · filed 2019-03-26 | $40.05M derived: sum of 4 quarters · filed 2019-03-26 |
| 2016-12-31 | $9.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $19.54M derived: sum of 2 quarters · filed 2019-03-26 | $30.85M derived: sum of 3 quarters · filed 2019-03-26 | $42.85M 10-K · filed 2019-03-26 |
| 2016-09-30 | $10.39M 10-Q · filed 2017-11-14 | $21.70M derived: sum of 2 quarters · filed 2017-11-14 | $33.70M 10-Q · filed 2017-11-14 | $46.37M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-06-30 | $11.31M 10-Q · filed 2017-08-14 | $23.31M 10-Q · filed 2017-08-14 | $35.98M derived: sum of 3 quarters · filed 2018-03-20 | $43.72M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-03-31 | $12.00M 10-Q · filed 2017-05-11 | $24.67M derived: sum of 2 quarters · filed 2018-03-20 | $32.41M derived: sum of 3 quarters · filed 2018-03-20 | $39.91M derived: sum of 4 quarters · filed 2018-03-20 |
| 2015-12-31 | $12.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | $20.41M derived: sum of 2 quarters · filed 2018-03-20 | $27.91M derived: sum of 3 quarters · filed 2018-03-20 | $34.50M 10-K · filed 2018-03-20 |
| 2015-09-30 | $7.74M 10-Q · filed 2016-11-14 | $15.24M derived: sum of 2 quarters · filed 2016-11-14 | $21.83M 10-Q · filed 2016-11-14 | $26.18M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $7.50M 10-Q · filed 2016-08-10 | $14.10M 10-Q · filed 2016-08-10 | $18.44M derived: sum of 3 quarters · filed 2017-03-16 | $22.85M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $6.59M 10-Q · filed 2016-05-11 | $10.93M derived: sum of 2 quarters · filed 2017-03-16 | $15.34M derived: sum of 3 quarters · filed 2017-03-16 | $18.98M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $8.75M derived: sum of 2 quarters · filed 2017-03-16 | $12.39M derived: sum of 3 quarters · filed 2017-03-16 | $16.78M 10-K · filed 2017-03-16 |
| 2014-09-30 | $4.41M 10-Q · filed 2015-11-10 | $8.05M derived: sum of 2 quarters · filed 2015-11-10 | $12.44M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | $3.64M 10-Q · filed 2015-08-12 | $8.03M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | $4.39M 10-Q · filed 2015-06-18 | |||
| 2013-12-31 | $13.83M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |